Array of personal items

Request more information about BRONCHITOL® (mannitol) inhalation powder

If you would like to learn more about BRONCHITOL, have one of our sales representatives contact you, or get updates when they become available, please fill out the fields below.

I’m interested in:

By checking this box, I give Chiesi USA, Inc. permission to store my personal data and use that information to send me emails with information and updates on BRONCHITOL and confirm that I have read and agree to the terms of the Privacy Policy.

By checking this box, I give Chiesi USA, Inc. the right to store my personal data to respond to my request and confirm that I have read and agree to the terms of the Privacy Policy.






Eyeglasses and TicketsCar Keys and Mobile Phone

Medical Information

To request specific medical information about BRONCHITOL or to report adverse events or product complaints, please contact the Medical Information Department.

Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-1088 or www.fda.gov/medwatch.

Mail:

Chiesi USA, Inc.
175 Regency Woods Place
Suite 600 Cary, NC 27518

Phone:

1-888-661-9260

Email:

us.medical@chiesi.com

Fax:

(866) 443-3092

Contact Chiesi CareDirect®

Chiesi  CareDirect® Logo

Phone:

1-888-865-1222 toll-free,
Monday–Friday
from 9 am–6 pm EST

Email:

chiesicaredirect@caremetx.
com
      

Important Safety
Information

BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).

BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.

Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.

Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.

Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.

Please see Full Prescribing Information.

Indication

BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.

Please see Full Prescribing Information.